Literature DB >> 31718877

Pathological complete response of initially inoperable lung squamous cell carcinoma treated by immunochemotherapy: A case report.

Che-Pin Lin1, Yung-Chuan Sung2, Cheng-Yu Lo3, Ming-Hong Yen4.   

Abstract

Entities:  

Year:  2019        PMID： 31718877     DOI： 10.1016/j.asjsur.2019.10.008

Source DB:  PubMed          Journal:  Asian J Surg        ISSN： 1015-9584            Impact factor:   2.767


× No keyword cloud information.
  5 in total

1.  N 6 -Methyladenosine-Related Long Non-Coding RNAs Are Identified as a Potential Prognostic Biomarker for Lung Squamous Cell Carcinoma and Validated by Real-Time PCR.

Authors:  Wei Zhang; Qian Zhang; Zhefan Xie; Li Che; Tingting Xia; Xingdong Cai; Shengming Liu
Journal:  Front Genet       Date:  2022-06-03       Impact factor: 4.772

2.  Identification of Key Genes Related to Lung Squamous Cell Carcinoma Using Bioinformatics Analysis.

Authors:  Miaomiao Gao; Weikaixin Kong; Zhuo Huang; Zhengwei Xie
Journal:  Int J Mol Sci       Date:  2020-04-23       Impact factor: 5.923

3.  Identification and validation of an individualized prognostic signature of lung squamous cell carcinoma based on ferroptosis-related genes.

Authors:  Xiayao Diao; Chao Guo; Lei Liu; Guige Wang; Shanqing Li
Journal:  Thorac Cancer       Date:  2021-10-20       Impact factor: 3.500

4.  Successful treatment of two patients with unresectable lung squamous cell carcinoma with tislelizumab regardless of programmed death-ligand 1 expression: a report of two cases.

Authors:  Qiaoyuan Wu; Yunliang Cao; Yi Li; Ni Jiang; Hui Dong; Yudi Dong; Fang Chen; Guojun Yue; Qing Luo
Journal:  Anticancer Drugs       Date:  2022-01-01       Impact factor: 2.248

5.  Dramatic response to immunochemotherapy followed by salvage surgery in an elderly lung cancer patient.

Authors:  Yoshio Okano; Michihiro Kunishige; Yoshihiro Kondo; Naoki Kadota; Atsushi Morishita; Keishi Naruse; Hisanori Machida; Nobuo Hatakeyama; Hiroyuki Hino; Tsutomu Shinohara; Shoji Sakiyama; Eiji Takeuchi
Journal:  Thorac Cancer       Date:  2021-12-20       Impact factor: 3.500
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.